Ustekinumab (Stelara) by Janssen Biotech Biosimilars Pipeline Review 2023 | Information on Approved Drugs and Drug Candidates in Research and Development as Biosimilar Antibodies

The “Ustekinumab (Stelara) Biosimilars Pipeline Review” report has been added to ResearchAndMarkets.com’s offering.

This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Stelara (ustekinumab).

Developed by Janssen Biotech, the blockbuster therapeutic antibody STELARA (INN: ustekinumab) is an approved human interleukin-12 and interleukin-23 antagonist indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients (6 years or older) who are candidates for phototherapy or systemic therapy, active psoriatic arthritis in adults, as well as for adult patients with moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis. Stelara was approved in the US and EU in 2009. The Stelara patent expires September 2023 in the United States.

Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product.

This product consists of:

  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
  • Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).
  • One-month online access to the publisher’s database

For more information about this report visit https://www.researchandmarkets.com/r/x57k10

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other Market Reports

The wearable medical devices market report provides a full list of key companies, their strategies, and the latest developments.
The global spinal fusion devices market is on track to achieve significant growth, with projections suggesting an increase in market size to US$ 9.99 Billion by 2030.
he global orthopedic devices market size is anticipated to reach USD 103.9 billion by 2030 and it is projected to grow at a CAGR of 5.3% from 2024 - 2030
The global laboratory proficiency testing market size is expected to reach USD 2.13 billion by 2030, expanding at a CAGR of 6.6% from 2024 to 2030.

By using this website you agree to accept Medical Device News Magazine Privacy Policy